€699,00 Tax included, shipping
calculated at checkout

Developed in collaboration with leading clinical research centers, Nurosym harnesses advanced neuromodulation technology in a sleek and easy - to - use wearable device.

Nurosym sends patented electrical signals to the brain via the vagus nerve, activating specific therapeutic mechanisms that can counter dysregulation in the nervous system and significantly improve health outcomes, as proven by clinical studies. Nurosym is a certified medical device and the most studied non-invasive vagal neuromodulation system in the world.

Certified Safe Medical Device
30+ Clinical Studies
2M+ happy patient sessions
Recommended by Doctors
30 Day Money Back Guarantee
100% Secure payment
International Shipping

How it works

Nurosym sends patented electrical impulses to the brain via the vagus nerve, activating the body's self-repair mode, improving Heart Rate Variability, reducing inflammation, and enhancing cognitive functions.

Clinically Validated Results

Nurosym is pioneering a new class of treatment that uses bioelectrical signals targeted to neural circuits of organs, treating disease without surgery or drugs. In 30+ Clinical Trials Nurosym demonstrated the following health benefits:

How to use

How to use


Nurosym has been evaluated in randomised placebo controlled clinical trials and now used widely with over 2M treatment sessions and 0 serious adverse events have been reported.

CE certified medical device & FDA Non-Significant Risk Designation

Over 2M treatment sessions and 0 serious adverse events

If you are not sure if Nurosym is right for you, contact a doctor or a certified healthcare professional.

If you do not have a doctor you can contact, please reach out to our support and we’ll help connect you with the right person.

or Contact Support


Hear from those who've experienced positive changes in their health and well-being.

What's in the box?

Patient stories

We've got the answers

Your frequently asked questions answered.

  • If you try Nurosym daily for 30 days and aren’t happy with your results, we’ll send you a full refund of your Nurosym Kit. No questions asked.
  • Given the remarkable results Nurosym has had in rigorously controlled clinical trials, we’re confident in its health-restoring effects.
  • Our goal will always be to restore our collective health - restoring health for as many people as we can and in turn, restoring the health of our planet.
  • If Nurosym doesn’t work for you for any reason, we’re happy to send you a refund.
  • This refund period is available 30 days after the date of purchase and expires the following week (37 days after the date of purchase).
  • The refund will be issued once we receive your tracking code for the return.
  • To receive a refund, Contact us
  • We ship to Europe, the UK and selected countries worldwide. If you can check out on our website, you can assume we can ship to you.
  • We ship from Netherlands
  • We ship within 24h
  • You should receive your device within a few days after shipping depending on your location
  • There should not be any extra costs if you are inside the EU. If you are outside of the EU, you may be liable for import fees, which are out of our control.
  • We know the impact Nurosym can have if used daily for 30 days, this is why we offer our guarantee. If you aren't happy after using Nurosym daily for 30 days, you can claim a full refund of your Nurosym Kit. This refund period is available 30 days after the date of purchase and expires the following week (37 days after the date of purchase).

Nurosym is shipped via priority tracked and signed couriers, so delivery times will vary based on shipping location. When you checkout, you’ll receive an estimated shipping time for your order.

We offer a one year warranty on Nurosym and a three month warranty on accessories.

  • Patients with an active implantable medical device, such as a cardiac pacemaker, hearing aid implant, or any implanted metallic or electronic device.
  • Patients with a history of atherosclerotic cardiovascular disease, congestive heart failure (CHF), known severe coronary artery disease or recent myocardial infarction (within 5 years).
  • Patients with diagnosed bradycardia.
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy).
  • Paediatric patients (under 18 years of age).
  • Pregnant woment
  • If you are not sure if Nurosym is right for you, contact a doctor or a certified healthcare professional.
  • If you do not have a doctor you can contact, please reach out to our support and we’ll help connect you with the right person.
  • Nurosym is considered low risk when used in accordance with the instructions for use.
  • Adverse effects are usually rare, mild and resolve shortly after treatment is completed.
  • The most common being a low incidence of skin irritation (tingling/pain/redness/itching) at the site of electrode placement during long term application.
  • No serious adverse events have been reported.
  • Other rare risks this type of technology include; light-headedness/dizziness, fatigue, shortness of breath, headaches, abnormal heart rhythm.
  • If you experience any adverse effects after using Nurosym, discontinue use and contact support.

Yes, Nurosym is considered safe when used as intended.

Nurosym is a certified medical device (CE Mark) in Europe. It has also received FDA Non-Significant Risk Designation in multiple studies in the US.

This means:

  • It has been audited by medical regulators
  • It is based on rigorous scientific evidence
  • The benefits outweighs the risks
  • It has demonstrated clinical efficacy
  • It has strict quality management systems
  • Be sure to read the important safety information before use.
  • Nurosym has been evaluated in randomised placebo controlled clinical trials and now used widely with over 2M treatment sessions and 0 serious adverse events have been reported.
  • Its safety has been confirmed in multiple clinical studies.

You do not need a prescription to purchase Nurosym however it is recommended that you consult with your doctor if you are unsure about eligibility.

  • Many patients experience the benefits of Nurosym right after the first few sessions. Some start feeling the effects after a few weeks of consistent use.
  • Daily use and consistency is key.
  • As long as you can feel the sensation of neuromodulation during the session and it's not painful, you're doing it right.
  • If within 30 days you don't feel the benefits, contact our support.

Haven't found the answer to your question?

Contact our support who will be happy to answer all your questions

61% increase in Vagus Nerve Activity & improved Heart Rate Variability

Heart Rate Variability (HRV) is a biomarker of Parasympathetic “rest and digest” system activation, indicating a balanced nervous system often associated with increased vagus nerve activity. In clinical trials, a one-hour session of Nurosym favourably altered three key parameters of Heart Rate Variability (HRV), when compared to placebo. These findings indicate an activation of the parasympathetic "rest and digest" system, coupled with a decrease in the "fight or flight" response.

Health implications:
  1. Stress
  2. Anxiety
  3. Exercise recovery
  4. Longevity
  5. Dysautonomia

Parasym clinical trial, Geng et al., 2022, PLOS ONE

Figure (A) shows High Frequency HRV is significantly increased (*p=0.001). Figure (B) shows Low Frequency HRV is significantly decreased (*P=0.001). Figure (C) shows the ratio of LF to HF is significantly decreased (*p=0.002). It suggests a greater shift towards the parasympathetic side during Nurosym neuromodulation, indicating a more pronounced relaxation response.

(Figure A, B, C, D) The autonomic function response, Nurosym Neuromodulation favourably altered all HRV parameters (A: HF, B: RMSSD, C: pRR50, D: SDRR). Better effects were observed in people with a poorer baseline HRV ratio. Memory effect was observed, meaning HRV remains elevated after neuromodulation was stopped.

61% improvement in inflammation

Inflammation throughout the body and brain can contribute to diseases development, premature ageing and mental health problems.

Cytokines are the main biomarkers (measures) of inflammation in the body.

In a randomised controlled trial, inflammatory cytokines were significantly lower in the group that received Nurosym neuromodulation compared to the placebo group at the end of 3 months. The study presented the changes in two inflammatory biomarkers: Tumor necrosis factor (TNF)‐α and Interleukin (IL)‐8 after Nurosym therapy.

Health implications:
  1. Cardiovascular health (AF, HF, Hypertension)
  2. Anti-ageing & Longevity
  3. Muscle pain
  4. Chronic pain
  5. Mental health conditions
  6. Autoimmune conditions (e.g. Rheumatoid Arthritis, Crohn’s Disease)
  7. Post-viral syndromes (Long-Covid, Lyme Disease)
  8. IBS, GERD & other GI symptoms

Parasym clinical trial, Stavrakis et al., 2023, Journal of American Heart Association

(Figure A, B) In a three-month study employing the Nurosym device for heart failure patients, notable improvements (*P < 0.05) were noted in inflammatory biomarkers: (A) Tumor Necrosis Factor (TNF)‐α exhibited a ~23% reduction, while (B) Interleukin (IL)‐8 showed a marked ~61.3% reduction. The investigation specifically targeted participants with elevated baseline inflammation levels.

Reduced fatigue & increased energy

Significant improvement in fatigue scores after treatment (D0 vs. D10, p < 0.0001).

Fatigue was measured using the Pichot Fatigue Scale. Participants reported that the improvements in fatigue remained 1 week after stopping the treatment.


Parasym clinical trial, Verbanck et al., 2021, Adv Neurol Neurosci Res

(Figure) In the study fatigue was assessed using of the Pichot fatigue scale scores during treatment (D0: day 0, D5: day 5 and D10: day 10). The results revealed a substantial reduction in fatigue, registering approximately 48% and higly significant improvment (D0 vs. D10, p < 0.0001) after Nurosym neuromodulation treatment. The individual values and the median are shown.

45% improvement in depression symptoms & improved mood

Nurosym neuromodulation decreased depression symptoms & improved mood in only 5 days of treatment.

The Parasym study revealed that a ten-day treatment regimen of Nurosym led to significant improvements in participants, alleviating chronic symptoms of depression and brain fog.

Health implications:
  1. Memory & cognitive enhancement
  2. Productivity
  3. Brain Fog
  4. Alzheimer’s & Dementia
  5. Social functioning
  6. Long-Covid

Parasym clinical trial, Verbanck et al., 2021, Adv Neurol Neurosci Res

(Figure) The figure shows the evolution of the Beck depression scale (D0: day 0, D5: day 5 and D10: day 10). The results showed a noticeable improvement in mood, registering approximately 45% on the Beck Depression Scale. The individual values and the median are shown.

13% improvement in sleep

Parasym study involving daily Nurosym neuromodulatiom demonstrated significant improvements in global sleep scores over a 2-week period. In the group with an active neuromodulation program, there was a ~13% improvement in global sleep scores. Nurosym therapy may address sleep concerns in community-dwelling adults and it exhibits harmless effects on sleep improvement compared to drug-treatmeant.

Health implications:
  1. Energy
  2. Productivity
  3. Chronic disease & pain reduction
  4. Brain Fog
  5. Chronic Fatigue Syndrome (ME/CFS)
  6. Ageing & Longevity
  7. Memory & Cognitive enhancement
  8. Stress resilience

Parasym clinical trial, Jackowska et al., 2022, Autonomic Neuroscience

(Figure) The study assessed changes in global sleep scores (PSQI) in 68 individuals who underwent 14 days of either active Nuorsym neuromodulaton (blue and red lines) or sham stimulation (green and orange lines). The predictions, shown with 95% confidence intervals, considered various factors like sleep scores, time, group, phase, age, gender, and their interactions. tVNS: transcutaneous vagus nerve stimulation

30% improvement in memory & learning

Nurosym research explores enhancements in memory and neuroplasticity. Improved cognitive function is correlated with the parasympathetic nervous system, whereas cognitive decline is associated with the sympathetic nervous system.

Health implications:
  1. Cognitive enhancement and performance
  2. Memory function
  3. Problem-solving skills
  4. Alzheimer’s & Dementia
  5. Anti-ageing & Longevity
  6. Productivity
  7. Dementia risk reduction

Parasym clinical trial, Geng et al., 2022, PLOS ONE

(Figure A, B) Nurosym improves memory on learning tasks in comparison to placebo. (A) There was a significant benefit of Nurosym neuromodulation compared to placebo across all test questions. (B) This effect was driven by a significant benefit of Nurosym neuromodulation on memory questions.

(Figure) Nurosym neuromodulation paired with training significantly (*p < 0.05) improved speed performence on the Automaticity learning task compared to placebo controls. Nurosym neuromodulation also significantly (∗p < 0.05) improved percent correct on the Decoding learning task as compared to controls.

40% improvement in Long-Covid symptoms (fatigue, brain fog, pain)

In a study of patients experiencing chronic fatigue symptoms after Covid-19 infection, approximately 40% of the participants showed positive responses to treatment involving Nurosym neuromodulation, as evidenced by improvements in fatigue, brain fog, and widespread pain. Improvement in long COVID symptoms, such as persistent fatigue, brain fog, and respiratory issues, can enhance quality of life and reduced disability.

Health implications:
  1. Chronic Fatigue Syndrome (ME/CFS)
  2. Stress & Anxiety
  3. Depression
  4. Athletic Recovery
  5. Productivity
  6. Respiratory conditions

Parasym clinical trial, Verbanck et al., 2021, Adv Neurol Neurosci Res, Parasym clinical trial, Natelson et al., 2022, MedRxiv

(Figure A) A very significant improvement was observed after 10 treatment sessions. (D0 vs. D10: p < 0.0001). Reserach evaluated our proprietary neuromodulation on those suffering with Long-COVID symptoms such as Fatigue, cognitive problems, Depression, Pain etc. Treatment starts after baseline measurement at Day 0 (D0), ending on D10, with follow up measurements one week later (D17).

40% reduction in POTS symptoms

After two months of using Nurosym therapy, the active group experienced a significant reduction in postural tachycardia syndrome (POTS) compared to the sham group, as observed through heart rate variability analyses. Additionally, the active group showed lower levels of anti-autonomic autoantibodies (specifically α1-AR and β1-AR), indicating a potential improvement in autonomic function and a reduction in inflammation.

Health implications:
  1. Decreased inflammation
  2. Improved heart rate & rythm regulation
  3. Recuded risk of cardiovascular complications
  4. Post-trauma recovery
  5. Arrhythmias mitigation
  6. Oxygen level increase

Parasym clinical trial, Stavrakis et al., 2023, Heart Rhythm

(Figure A) effect of active Nurosym neuromodulation vs sham (placebo) stimulation on the postural change in heart rate [Δ(heart rate)] at 2 months. No adverse effects related to the device were observed. The analysis showed that postural tachycardia (without a significant drop in blood pressure) was significantly less in subjects who received Nurosym neuromodulation compared to control (postural increase in heart rate 18±10 bpm vs. 32±14 bpm, respectively, p=0.016).

50% improvement in blood vessel flexibility & improved circulation

Nurosym has demonstrated the ability to enhance blood circulation compared to a placebo. This improvement in blood circulation, or perfusion rate, is crucial for efficiently supplying oxygen and nutrients to tissues while removing waste products. Such enhancements contribute to overall health and longevity by optimizing blood supply to various organs.

Health implications:
  1. Oxygen and nutrient delivery to tissues
  2. Organ function
  3. Blood clots risk reduction
  4. Vascular disease risk reduction
  5. Varicose veins
  6. Fatigue

Parasym clinical trial, Dasari et al., 2021, Journal of Cardiac Failure

(Figure (A, B, C): (A) Pseudo color images on dorsum of left hand during (1) baseline, (2) occlusion, and (3) Postocclusive reactive hyperemia (PORH) phase. Blue color represents lower, red represents higher perfusion rates. (B, C) Changes in blood perfusion measured over nail bed area, before and after Nurosym neuromodulation (B) and sham (placebo) stimulation (C). Markedly higher perfusion rate was seen after Nurosym neuromodulation